We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Stock Moves -0.97%: What You Should Know
Read MoreHide Full Article
Humana (HUM - Free Report) closed the most recent trading day at $503.53, moving -0.97% from the previous trading session. This change was narrower than the S&P 500's 1.11% loss on the day. Elsewhere, the Dow lost 0.85%, while the tech-heavy Nasdaq added 0.1%.
Heading into today, shares of the health insurer had lost 2.27% over the past month, lagging the Medical sector's gain of 3.73% and the S&P 500's loss of 2.19% in that time.
Wall Street will be looking for positivity from Humana as it approaches its next earnings report date. In that report, analysts expect Humana to post earnings of $1.47 per share. This would mark year-over-year growth of 18.55%. Meanwhile, our latest consensus estimate is calling for revenue of $22.45 billion, up 6.63% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $25.05 per share and revenue of $92.79 billion, which would represent changes of +21.37% and +11.7%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Humana. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.24% lower within the past month. Humana is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Humana's current valuation metrics, including its Forward P/E ratio of 20.29. This valuation marks a premium compared to its industry's average Forward P/E of 19.67.
Also, we should mention that HUM has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - HMOs industry currently had an average PEG ratio of 1.22 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 216, which puts it in the bottom 15% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Stock Moves -0.97%: What You Should Know
Humana (HUM - Free Report) closed the most recent trading day at $503.53, moving -0.97% from the previous trading session. This change was narrower than the S&P 500's 1.11% loss on the day. Elsewhere, the Dow lost 0.85%, while the tech-heavy Nasdaq added 0.1%.
Heading into today, shares of the health insurer had lost 2.27% over the past month, lagging the Medical sector's gain of 3.73% and the S&P 500's loss of 2.19% in that time.
Wall Street will be looking for positivity from Humana as it approaches its next earnings report date. In that report, analysts expect Humana to post earnings of $1.47 per share. This would mark year-over-year growth of 18.55%. Meanwhile, our latest consensus estimate is calling for revenue of $22.45 billion, up 6.63% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $25.05 per share and revenue of $92.79 billion, which would represent changes of +21.37% and +11.7%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Humana. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.24% lower within the past month. Humana is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Humana's current valuation metrics, including its Forward P/E ratio of 20.29. This valuation marks a premium compared to its industry's average Forward P/E of 19.67.
Also, we should mention that HUM has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - HMOs industry currently had an average PEG ratio of 1.22 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 216, which puts it in the bottom 15% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.